FDA’s Special Protocol Rescissions Get U.S. Capitol, Venture Capital Attention
This article was originally published in The Pink Sheet Daily
House Appropriations Committee wants FDA to provide more justification when it changes a special protocol assessment.
You may also be interested in...
The FDA did not expect to meet many FY 2018 goals for on-time scheduling of formal PDUFA meetings or issuing written responses in lieu of meetings.
CBER Director Peter Marks says the "half-life" for the existing six gene therapy guidances likely is two to three years due to the fast pace of scientific discovery.
The meetings are tied to requirements from the 2016 21st Century Cures legislation. They could offer more development certainty for sponsors by allowing informal agreements with the agency on pre- and post-market issues.